Axela Biosciences provides comprehensive Targeted Protein Degrader (TPD) discovery and profiling services to support the development of next-generation therapeutics, including PROTACs, molecular glues, and other protein degradation modalities.

Their platform enables researchers to evaluate, validate, and optimize degraders that selectively eliminate disease-causing proteins through the ubiquitin–proteasome system and lysosomal degradation pathways.

Overview

Targeted Protein Degraders (TPDs) represent a transformative drug discovery approach that goes beyond traditional inhibition by inducing the complete removal of target proteins rather than simply blocking their function.

Axela supports TPD programs across early discovery through preclinical development by combining:

High-throughput screening systems
Quantitative protein degradation assays
Ligand binding and ternary complex characterization
Proteomics and pathway-level analysis
Translational biomarker readouts

This enables full-cycle evaluation of degrader efficacy, selectivity, and mechanism of action.

Core Capabilities

Axela Biosciences offers integrated TPD discovery services including:

PROTAC and molecular glue screening
Target protein degradation quantification (DC50, Dmax)
E3 ligase ligand binding assays (CRBN, VHL, MDM2, cIAP1, and others)
Ternary complex formation and stability analysis
Ubiquitination assays and pathway activation studies
High-content protein degradation readouts (Western blot, Simple Western, RPPA, IHC)
Proteome-wide selectivity profiling
Mechanism-of-action (MoA) studies
Assay Platforms

Axela uses a multi-platform approach to enable robust TPD evaluation:

NanoBRET assays for live-cell target engagement
AlphaLISA and HTRF binding assays
High-throughput flow cytometry
Simple Western and automated capillary electrophoresis systems
RPPA (Reverse Phase Protein Array) for broad signaling analysis
IHC for tissue-level validation
Cell permeability and stability assays (CETSA, PAMPA, Caco-2)

These platforms allow both biochemical and cell-based validation of degrader activity.

Discovery & Screening Services

Axela supports full-stage TPD discovery workflows:

Ligand identification and E3 ligase recruitment screening
Warhead optimization for target engagement
Degrader potency and dose-response profiling
Selectivity screening across protein families and pathways
Early ADME and cellular permeability assessment
Structure–activity relationship (SAR) support
Translational Applications

TPD services are widely used for:

Oncology drug development
Immunology and inflammation research
Neurodegenerative disease programs
Undruggable target exploration
Resistance mechanism studies
Biomarker discovery and validation
Why Axela Biosciences?

Axela combines ultra-sensitive detection platforms with multiplex proteomic and cellular systems to generate deep mechanistic insight from small sample inputs.

Their TPD discovery capabilities are designed to help biotech and pharma teams:

Expand druggable target space beyond traditional inhibitors
Rapidly evaluate degrader potency and selectivity
Translate early hits into clinically relevant candidates
Reduce cycle time from screening to validation